Drug Overview
Savaysa (edoxaban; Daiichi Sankyo) is a direct oral factor Xa inhibitor indicated for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE). Inhibition of factor Xa reduces thrombin generation and thrombus formation. Savaysa inhibits prothrombinase activity and thrombin-induced platelet aggregation, thus reducing blood clots.
Savaysa is also indicated for stroke prevention in atrial fibrillation.
Savaysa (edoxaban; Daiichi Sankyo) is a direct oral factor Xa inhibitor indicated for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE). Inhibition of factor Xa reduces thrombin generation and thrombus formation. Savaysa inhibits prothrombinase activity and thrombin-induced platelet aggregation, thus reducing blood clots.
Savaysa is also indicated for stroke prevention in atrial fibrillation.
Table of Contents
OVERVIEWDrug Overview
Product Profiles
Savaysa: Stroke prevention in atrial fibrillation (SPAF)
Savaysa: Venous thromboembolism (VTE)
List of Figures
Figure 1: Savaysa for SPAF - SWOT analysis
Figure 2: Drug assessment summary of Savaysa for SPAF
Figure 3: Drug assessment summary of Savaysa for SPAF
Figure 4: Savaysa sales for SPAF across the US, Japan, and five major EU markets, by country, 2017-26
Figure 5: Savaysa for venous thromboembolism - SWOT analysis
Figure 6: Drug assessment summary of Savaysa for venous thromboembolism
Figure 7: Drug assessment summary Savaysa for venous thromboembolism
Figure 8: Savaysa sales forecast for VTE in the US, Japan, and five major EU markets, by country, 2017-26
List of Tables
Table 1: Savaysa drug profile
Table 2: Savaysa pivotal trial data in SPAF
Table 3: Savaysa late-phase trial data in SPAF
Table 4: Savaysa ongoing late-phase clinical trials in SPAF
Table 5: Savaysa sales for SPAF across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 6: Savaysa drug profile
Table 7: Savaysa pivotal trial data in venous thromboembolism
Table 8: Savaysa late-phase trial data in venous thromboembolism
Table 9: Savaysa ongoing late-phase clinical trial in venous thromboembolism
Table 10: Savaysa sales for VTE in the US, Japan, and five major EU markets, by country ($m), 2017-26
